Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase I clinical trial for the treatment of patients with hepatocellular carcinoma (liver cancer).
ADP-A2AFP Phase 1 clinical trial
This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti- tumor activity of Adaptimmune's ADP-A2AFP therapeutic candidate. The ongoing study will include patients who have advanced hepatocellular carcinoma (liver cancer), which has grown or returned after being treated, and who are HLA-A*02 positive and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein. . Patients who did not tolerate or refused other therapies may also participate. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2AFP SPEAR T-cell therapy. Further details are available via the link below.View Clinical Trial
Please visit our Publications page for more information on ADP-A2AFP